Benchmarking CRISPR-BP34 for point-of-care melioidosis detection in low-income and middle-income countries: a molecular diagnostics study

Pakdeerat S.; Boonklang P.; Angchagun K.; Chomkatekaew C.; Apichaidejudom N.; Dokket Y.; Faosap A.; Wongsuwan G.; Wuthiekanun V.; Aramrueung P.; Khamnoi P.; Thananchai H.; Siriboon S.; Chamnan P.; Peacock SJ.; Day NPJ.; Thomson NR.; Uttamapinant C.; Wongpalee SP.; Chewapreecha C.

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Benchmarking CRISPR-BP34 for point-of-care melioidosis detection in low-income and middle-income countries: a molecular diagnostics study

Pakdeerat S., Boonklang P., Angchagun K., Chomkatekaew C., Apichaidejudom N., Dokket Y., Faosap A., Wongsuwan G., Wuthiekanun V., Aramrueung P., Khamnoi P., Thananchai H., Siriboon S., Chamnan P., Peacock SJ., Day NPJ., Thomson NR., Uttamapinant C., Wongpalee SP., Chewapreecha C.

Original publication

DOI

10.1016/s2666-5247(23)00378-6

Type

Journal

The Lancet Microbe

Publisher

Elsevier

Publication Date

01/03/2024

Keywords

3 Good Health and Well Being, 3202 Clinical Sciences, Clinical Trials and Supportive Activities, 4.1 Discovery and preclinical testing of markers and technologies, 32 Biomedical and Clinical Sciences, 4 Detection, screening and diagnosis, Infection, 4.2 Evaluation of markers and technologies, Clinical Research